Barclays analyst Matt Miksic lowered the firm’s price target on DexCom (DXCM) to $64 from $67 and keeps an Underweight rating on the shares. The company’s investor day set the bar for 10% growth annually for the next five years, slightly below consensus, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Morning News Wrap-Up, 5/15/26: Today’s Biggest Stock Market Stories!
- Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports
- Why Is Dexcom Stock (DXCM) Soaring Today?
- Early notable gainers among liquid option names on May 15th
- Dexcom: Buy Rating Reaffirmed on Sustained Double-Digit Growth Outlook, Margin Expansion, and Governance Enhancements